Coronavirus Main Proteinase (3CLpro) Structure: Basis for Design of Anti-SARS Drugs

K. Anand, John Ziebuhr, P. Wadhwani, R. Hilgenfeld, J.R. Mesters

Research output: Contribution to journalArticle

643 Citations (Scopus)

Abstract

A novel coronavirus has been identified as the causative agent of severe acute respiratory syndrome (SARS). The viral main proteinase (Mpro, also called 3CLpro), which controls the activities of the coronavirus replication complex, is an attractive target for therapy. We determined crystal structures for human coronavirus (strain 229E) Mpro and for an inhibitor complex of porcine coronavirus [transmissible gastroenteritis virus (TGEV)] Mpro, and we constructed a homology model for SARS coronavirus (SARS-CoV) Mpro. The structures reveal a remarkable degree of conservation of the substrate-binding sites, which is further supported by recombinant SARS-CoV Mpro-mediated cleavage of a TGEV Mpro substrate. Molecular modeling suggests that available rhinovirus 3Cpro inhibitors may be modified to make them useful for treating SARS.
Original languageEnglish
Pages (from-to)1763-1767
Number of pages5
JournalScience
Volume300(5626)
Issue number5626
DOIs
Publication statusPublished - 13 Jun 2003

ASJC Scopus subject areas

  • General

Fingerprint Dive into the research topics of 'Coronavirus Main Proteinase (3CL<sup>pro</sup>) Structure: Basis for Design of Anti-SARS Drugs'. Together they form a unique fingerprint.

  • Cite this

    Anand, K., Ziebuhr, J., Wadhwani, P., Hilgenfeld, R., & Mesters, J. R. (2003). Coronavirus Main Proteinase (3CLpro) Structure: Basis for Design of Anti-SARS Drugs. Science, 300(5626)(5626), 1763-1767. https://doi.org/10.1126/science.1085658